Marksans Pharma Gelecekteki Büyüme
Future kriter kontrolleri 4/6
Marksans Pharma kazanç ve gelirin sırasıyla yıllık 22.3% ve 16.2% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 22.4% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 18.7% olacağı tahmin edilmektedir.
Anahtar bilgiler
22.3%
Kazanç büyüme oranı
22.4%
EPS büyüme oranı
Pharmaceuticals kazanç büyümesi | 17.7% |
Gelir büyüme oranı | 16.2% |
Gelecekteki özkaynak getirisi | 18.7% |
Analist kapsamı | Low |
Son güncelleme | 14 Nov 2024 |
Gelecekteki son büyüme güncellemeleri
Recent updates
Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?
Oct 24Optimistic Investors Push Marksans Pharma Limited (NSE:MARKSANS) Shares Up 45% But Growth Is Lacking
Sep 21Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company
Jul 28Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)
Jun 07Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?
May 31Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)
Feb 16Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors
Jan 26We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease
Dec 02Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly
Jun 21Robust Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)
Nov 17This Is The Reason Why We Think Marksans Pharma Limited's (NSE:MARKSANS) CEO Deserves A Bump Up To Their Compensation
Sep 16Marksans Pharma (NSE:MARKSANS) Is Increasing Its Dividend To ₹0.25
Sep 01Marksans Pharma (NSE:MARKSANS) Could Easily Take On More Debt
Jun 14Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?
May 27Is Marksans Pharma (NSE:MARKSANS) A Risky Investment?
Feb 19Marksans Pharma Limited's (NSE:MARKSANS) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Feb 04Here's Why We Think Marksans Pharma (NSE:MARKSANS) Is Well Worth Watching
Jan 20Do Institutions Own Marksans Pharma Limited (NSE:MARKSANS) Shares?
Jan 05Shareholders Are Thrilled That The Marksans Pharma (NSE:MARKSANS) Share Price Increased 250%
Dec 21What Can We Conclude About Marksans Pharma's (NSE:MARKSANS) CEO Pay?
Dec 06Kazanç ve Gelir Büyüme Tahminleri
Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
---|---|---|---|---|---|
3/31/2027 | 35,839 | 6,047 | 4,354 | 4,360 | 3 |
3/31/2026 | 30,751 | 4,913 | 3,460 | 3,868 | 3 |
3/31/2025 | 26,607 | 3,970 | 1,963 | 2,945 | 2 |
9/30/2024 | 23,787 | 3,470 | 520 | 2,169 | N/A |
6/30/2024 | 22,680 | 3,338 | N/A | N/A | N/A |
3/31/2024 | 21,774 | 3,137 | 216 | 2,304 | N/A |
12/31/2023 | 21,034 | 3,164 | N/A | N/A | N/A |
9/30/2023 | 19,971 | 2,965 | 894 | 2,528 | N/A |
6/30/2023 | 19,184 | 2,743 | N/A | N/A | N/A |
3/31/2023 | 18,521 | 2,663 | 1,838 | 2,374 | N/A |
12/31/2022 | 17,842 | 2,123 | N/A | N/A | N/A |
9/30/2022 | 16,670 | 2,004 | 972 | 1,286 | N/A |
6/30/2022 | 15,756 | 1,847 | N/A | N/A | N/A |
3/31/2022 | 14,908 | 1,868 | 529 | 993 | N/A |
12/31/2021 | 14,069 | 2,367 | N/A | N/A | N/A |
9/30/2021 | 14,026 | 2,473 | 883 | 1,336 | N/A |
6/30/2021 | 14,064 | 2,518 | N/A | N/A | N/A |
3/31/2021 | 13,762 | 2,385 | 1,322 | 1,786 | N/A |
12/31/2020 | 13,817 | 2,018 | N/A | N/A | N/A |
9/30/2020 | 13,142 | 1,724 | 1,839 | 2,478 | N/A |
6/30/2020 | 12,203 | 1,476 | N/A | N/A | N/A |
3/31/2020 | 11,344 | 1,208 | 1,734 | 2,333 | N/A |
12/31/2019 | 10,463 | 879 | N/A | N/A | N/A |
9/30/2019 | 9,972 | 834 | 66 | 416 | N/A |
6/30/2019 | 10,099 | 780 | N/A | N/A | N/A |
3/31/2019 | 10,001 | 804 | 142 | 274 | N/A |
12/31/2018 | 9,523 | 666 | N/A | N/A | N/A |
9/30/2018 | 9,223 | 582 | N/A | N/A | N/A |
6/30/2018 | 9,272 | 463 | N/A | N/A | N/A |
3/31/2018 | 9,127 | 358 | N/A | 501 | N/A |
12/31/2017 | 8,918 | 343 | N/A | N/A | N/A |
9/30/2017 | 8,949 | 275 | N/A | N/A | N/A |
6/30/2017 | 8,015 | 187 | N/A | N/A | N/A |
3/31/2017 | 7,672 | 113 | N/A | 141 | N/A |
12/31/2016 | 7,926 | 70 | N/A | N/A | N/A |
9/30/2016 | 7,948 | 136 | N/A | N/A | N/A |
6/30/2016 | 8,699 | 481 | N/A | N/A | N/A |
3/31/2016 | 8,933 | 785 | N/A | 308 | N/A |
12/31/2015 | 8,536 | 1,093 | N/A | N/A | N/A |
9/30/2015 | 8,495 | 1,191 | N/A | N/A | N/A |
6/30/2015 | 8,045 | 1,154 | N/A | N/A | N/A |
3/31/2015 | 7,967 | 1,094 | N/A | 1,545 | N/A |
12/31/2014 | 7,850 | 950 | N/A | N/A | N/A |
9/30/2014 | 7,405 | 897 | N/A | N/A | N/A |
6/30/2014 | 6,914 | 786 | N/A | N/A | N/A |
3/31/2014 | 6,300 | 719 | N/A | 648 | N/A |
12/31/2013 | 5,950 | 1,020 | N/A | N/A | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: MARKSANS 'nin tahmini kazanç büyümesi (yıllık 22.3% ) tasarruf oranının ( 6.7% ) üzerindedir.
Kazançlar ve Piyasa: MARKSANS şirketinin kazançlarının (yıllık 22.3% ) Indian pazarından (yıllık 18% ) daha hızlı büyümesi öngörülüyor.
Yüksek Büyüme Kazançları: MARKSANS şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artması bekleniyor.
Gelir ve Pazar: MARKSANS şirketinin gelirinin (yıllık 16.2% ) Indian pazarından (yıllık 10.5% ) daha hızlı büyümesi öngörülüyor.
Yüksek Büyüme Geliri: MARKSANS şirketinin gelirinin (yıllık 16.2% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: MARKSANS 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 18.7 %).